Results 121 to 130 of about 36,016 (212)

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort. [PDF]

J Antimicrob Chemother
Ciccullo A, Baldin G, Cervo A, Oreni L, Mazzitelli M, Gasparro G, Menozzi M, Cesaretti M, Bassani F, Lagi F, Lombardi F, Giacomelli A, Borghetti A, Fabbiani M, Rusconi S, Cattelan A, Antinori S, Mussini C, Di Giambenedetto S.   +18 more
europepmc   +1 more source

Toxicity of the Antiretrovirals Lamivudine, Dolutegravir, and Tenofovir on the Microalga <i>Chlorella vulgaris</i>. [PDF]

ACS Omega
Souza-Silva G, Alcantara M, Moreira C, Starling MC, Souza C, Nunes K, Pereira C, Mol M, Silveira M.   +8 more
europepmc   +1 more source

Oral Lamivudine for Extended HIV Postnatal Prophylaxis. [PDF]

Paediatr Drugs
Van de Perre P, Meda N, Tassembedo S, Moles JP, Kankasa C, Mennecier A, Mwiya M, Nagot N, Tylleskär T.   +8 more
europepmc   +1 more source

Neonatal Lactic Acidosis Associated With Antiretroviral Exposure: A Case Report. [PDF]

Cureus
Mercado J, Rivera L, Droz López A, Poventud Y, Andino-Colón C.   +4 more
europepmc   +1 more source

Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy. [PDF]

Clin Infect Dis
Mohareb AM, Boyd A.
europepmc   +1 more source

Use of dual ART in individuals with different HBV serological patterns. [PDF]

Curr Opin HIV AIDS
Swaine T, Bhagani S.
europepmc   +1 more source

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B

, 2005
AIM: To investigate the efficacy of combination treatment of IFN-alpha and lamivudine compared to lamivudine monotherapy, after 24 mo of administration in HBeAg-negative hepatitis B patients.
Raptis, Sotiris, Tsianos, Epameinondas V., Trikalinos, Thomas A., Bethanis, Sotiris, Avgerinos, Alec, Filis, Spyros, Economou, Michalis, Manolakopoulos, Spilios, Tzourmakliotis, Dimitrios   +8 more
core  

R263K-associated dolutegravir resistance on tenofovir, lamivudine and dolutegravir: Implications for earlier genotyping and regimen optimisation. [PDF]

S Afr J Infect Dis
Naidoo S.
europepmc   +1 more source

Clinical and biological risk factors influencing infant HIV status: a case study of Kisenyi Health Center IV, Kampala, Uganda. [PDF]

BMC Infect Dis
Bagonza FX, Asiimwe JB, Wamono F, Nsimbe D.   +3 more
europepmc   +1 more source

Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance. [PDF]

Adv Ther
Sebata A, Nagao T, Matsukawa T, Maeno Y, Suzuki M, Yoshikawa Y, Ibe S, Fukuda A, Wang D.   +8 more
europepmc   +1 more source